A2M received Notice of deferral of FDA consideration of enforcement discretion

Aug 10, 2022

The a2 Milk Company (ASX: A2M) announced that it received notice from the US Food and Drug Administration that the FDA is deferring additional consideration of A2M s request for enforcement discretion to import infant milk formula (IMF) products into the US.

International Dairy Foods Association has advised that similar letters have been sent to all awaiting enforcement discretion candidates, demonstrating that the FDA is deferring any more review currently of all awaiting applications.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au